HUE018715T2 - Intravitreális beadásra alkalmas VEGF antagonista készítmények - Google Patents

Intravitreális beadásra alkalmas VEGF antagonista készítmények

Info

Publication number
HUE018715T2
HUE018715T2 HUE11157965A HUE11157965A HUE018715T2 HU E018715 T2 HUE018715 T2 HU E018715T2 HU E11157965 A HUE11157965 A HU E11157965A HU E11157965 A HUE11157965 A HU E11157965A HU E018715 T2 HUE018715 T2 HU E018715T2
Authority
HU
Hungary
Prior art keywords
formulations suitable
vegf antagonist
intravitreal administration
antagonist formulations
intravitreal
Prior art date
Application number
HUE11157965A
Other languages
English (en)
Hungarian (hu)
Inventor
Eric Furfine
Daniel Dix
Kenneth Graham
Kelly Frye
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE018715(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE018715T2 publication Critical patent/HUE018715T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HUE11157965A 2006-06-16 2007-06-14 Intravitreális beadásra alkalmas VEGF antagonista készítmények HUE018715T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81448406P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
HUE018715T2 true HUE018715T2 (hu) 2024-10-28

Family

ID=38834013

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11157965A HUE018715T2 (hu) 2006-06-16 2007-06-14 Intravitreális beadásra alkalmas VEGF antagonista készítmények
HUE15169936A HUE053612T2 (hu) 2006-06-16 2007-06-14 Intravitreális bevitelre alkalmas VEGF-antagonista készítmények

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15169936A HUE053612T2 (hu) 2006-06-16 2007-06-14 Intravitreális bevitelre alkalmas VEGF-antagonista készítmények

Country Status (22)

Country Link
US (16) US7608261B2 (cg-RX-API-DMAC7.html)
EP (4) EP3753548A1 (cg-RX-API-DMAC7.html)
JP (2) JP5216002B2 (cg-RX-API-DMAC7.html)
KR (1) KR101406811B1 (cg-RX-API-DMAC7.html)
CN (2) CN101478949A (cg-RX-API-DMAC7.html)
AU (1) AU2007261536C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713749B8 (cg-RX-API-DMAC7.html)
CA (1) CA2654510C (cg-RX-API-DMAC7.html)
CY (2) CY1114244T1 (cg-RX-API-DMAC7.html)
DK (2) DK2364691T3 (cg-RX-API-DMAC7.html)
ES (2) ES2861898T3 (cg-RX-API-DMAC7.html)
HK (1) HK1204580A1 (cg-RX-API-DMAC7.html)
HU (2) HUE018715T2 (cg-RX-API-DMAC7.html)
IL (1) IL195788A (cg-RX-API-DMAC7.html)
LT (1) LT2944306T (cg-RX-API-DMAC7.html)
MX (1) MX2008016124A (cg-RX-API-DMAC7.html)
PL (2) PL2364691T3 (cg-RX-API-DMAC7.html)
PT (2) PT2364691E (cg-RX-API-DMAC7.html)
RU (1) RU2432155C3 (cg-RX-API-DMAC7.html)
SI (2) SI2364691T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007149334A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200809827B (cg-RX-API-DMAC7.html)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ617083A (en) * 2003-08-27 2015-04-24 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
PL2586459T3 (pl) 2005-03-25 2017-12-29 Regeneron Pharmaceuticals, Inc. Formulacje antagonistów vegf
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
DE602008006064D1 (de) 2007-01-18 2011-05-19 Eveready Battery Inc Rasiersystem mit gaserzeugungszelle
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2012101252A2 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
KR102218223B1 (ko) 2011-11-18 2021-02-22 리제너론 파마슈티칼스 인코포레이티드 폴리머 단백질 미립자
CN103212075B (zh) * 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
JO3533B1 (ar) 2012-01-23 2020-07-05 Regeneron Pharma تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
WO2013181495A2 (en) * 2012-06-01 2013-12-05 Ophthotech Corporation Compositions comprising an anti-pdgf aptamer and a vegf antagonist
HUE055994T2 (hu) 2012-06-01 2022-01-28 Novartis Ag Fecskendõ
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
AU2013100360B4 (en) * 2012-07-03 2013-05-16 Novartis Ag Device
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
US8922746B2 (en) 2012-08-06 2014-12-30 Shenzhen China Star Optoelectronics Technology Co., Ltd Liquid crystal injection device and liquid crystal container thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EA201592267A1 (ru) 2013-06-07 2016-04-29 Ридженерон Фармасьютикалз, Инк. Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
KR20230152151A (ko) 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
CN103622961B (zh) * 2013-09-06 2016-03-02 武汉光谷百桥国际生物科技有限公司 一种非肽类缓激肽b2受体激动剂在促进毛发生长方面的应用
EA201690889A1 (ru) 2013-11-12 2016-11-30 Санофи Байотекнолоджи Режимы дозирования для применения ингибиторов pcsk9
EP3071181B1 (en) * 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AU2016210918A1 (en) 2015-01-28 2017-07-13 Pfizer Inc., Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
AU2016308111A1 (en) 2015-08-18 2018-03-01 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
EA036623B1 (ru) * 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Стабильные белковые композиции
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
WO2017087798A1 (en) * 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
KR102854749B1 (ko) 2015-11-18 2025-09-04 에스아이오2 메디컬 프로덕츠, 엘엘씨 안과 제제용 제약 패키지
EP4276199A3 (en) 2015-12-03 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
ES2981791T3 (es) * 2015-12-16 2024-10-10 Regeneron Pharma Composiciones y métodos para fabricar micropartículas de proteína
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3407868A1 (en) * 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
CN117593361A (zh) 2016-07-29 2024-02-23 里珍纳龙药品有限公司 具有集成电子视觉检查的组装线
WO2018034885A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
MX2019004316A (es) 2016-10-25 2019-08-05 Regeneron Pharma Metodos y sistemas para analisis de datos cromatograficos.
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
AU2018266324B2 (en) 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
US20200255496A1 (en) 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN111201042B (zh) 2017-09-19 2024-05-10 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
EP3709971A2 (en) 2017-11-17 2020-09-23 Amgen Inc. Vegfr-fc fusion protein formulations
EP3713591A1 (en) 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
EP3724653B1 (en) * 2017-12-13 2025-01-15 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR20250002808A (ko) * 2017-12-22 2025-01-07 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP3761953A1 (en) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
JP2021521107A (ja) * 2018-04-05 2021-08-26 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ｔｅｒｔ−ブタノールレベルを低下させた医薬組成物
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
CN116585466A (zh) * 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
MX2022001330A (es) * 2019-08-01 2022-03-04 Gennova Biopharmaceuticals Ltd Composicion oftalmica de bevacizumab.
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.
CA3159586A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
MX2022014241A (es) 2020-05-11 2022-12-02 Regeneron Pharma Eliminacion viral por retencion de ph bajo.
EP4186492A4 (en) 2020-07-24 2024-08-14 Pangen Biotech Inc. Ophthalmic liquid composition
AU2021315381A1 (en) * 2020-07-31 2023-03-02 Celltrion Inc. Stable pharmaceutical preparation
CN112245569B (zh) * 2020-11-18 2024-05-28 通化东宝药业股份有限公司 一种稳定的阿柏西普制剂及其制备方法
KR102720956B1 (ko) * 2020-12-15 2024-10-24 삼천당제약주식회사 안과용 제형을 포함하는 시린지
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
WO2023153535A1 (ko) * 2022-02-09 2023-08-17 삼천당제약주식회사 안과용 제형을 포함하는 시린지
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1046492A (en) 1907-11-14 1912-12-10 Walter Chisholm Ranson Flushing apparatus.
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CA2370246C (en) 1999-04-16 2017-03-21 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6777429B1 (en) 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7033604B2 (en) 2001-07-06 2006-04-25 Sucampo Ag Composition for topical administration
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
EA006746B1 (ru) * 2001-11-09 2006-04-28 Айтек Фармасьютикалз Способы лечения глазных неоваскулярных заболеваний
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
MXPA05008972A (es) 2003-03-28 2005-11-04 Regeneron Pharma Metodos de tratamiento de diabetes por bloqueo de la actividad mediada por factor de crecimiento endotelial vascular.
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20040266688A1 (en) 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
EP1631317A2 (en) 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
AU2004264891A1 (en) 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist in combination with radiation therapy
NZ617083A (en) 2003-08-27 2015-04-24 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20050261243A1 (en) 2004-04-21 2005-11-24 Peyman Gholam A Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
JP2008502738A (ja) 2004-06-10 2008-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006015297A2 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
WO2006023665A2 (en) 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
EP2324848A3 (en) * 2004-10-21 2011-09-14 Genentech, Inc. Method for treating intraocular neovascular diseases
AU2006214658A1 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PL2586459T3 (pl) 2005-03-25 2017-12-29 Regeneron Pharmaceuticals, Inc. Formulacje antagonistów vegf
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20090202855A1 (en) 2008-01-09 2009-08-13 Saxton David M Porous sliding bearing and method of construction thereof
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
KR20250002808A (ko) 2017-12-22 2025-01-07 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물

Also Published As

Publication number Publication date
US20130274189A1 (en) 2013-10-17
WO2007149334A2 (en) 2007-12-27
PL2944306T3 (pl) 2021-07-12
US7807164B2 (en) 2010-10-05
US9914763B2 (en) 2018-03-13
RU2432155C2 (ru) 2011-10-27
US20070293432A1 (en) 2007-12-20
US20110257601A1 (en) 2011-10-20
DK2364691T3 (da) 2013-07-01
ES2406764T3 (es) 2013-06-10
CY1124265T1 (el) 2021-10-29
JP2009540001A (ja) 2009-11-19
US20250042972A1 (en) 2025-02-06
KR101406811B9 (ko) 2025-09-25
US20180155408A1 (en) 2018-06-07
CY1114244T1 (el) 2016-08-31
US20140323983A1 (en) 2014-10-30
BRPI0713749B8 (pt) 2021-05-25
DK2944306T3 (da) 2021-03-08
EP2364691A1 (en) 2011-09-14
US20160213608A1 (en) 2016-07-28
BRPI0713749B1 (pt) 2021-03-02
US11084865B2 (en) 2021-08-10
PT2944306T (pt) 2021-02-15
KR20090018807A (ko) 2009-02-23
US20230374108A1 (en) 2023-11-23
AU2007261536B2 (en) 2012-02-16
IL195788A (en) 2014-02-27
HK1204580A1 (en) 2015-11-27
CA2654510A1 (en) 2007-12-27
LT2944306T (lt) 2021-02-25
CA2654510C (en) 2015-03-17
EP3753548A1 (en) 2020-12-23
US9340594B2 (en) 2016-05-17
US20250257118A1 (en) 2025-08-14
JP5216002B2 (ja) 2013-06-19
AU2007261536A1 (en) 2007-12-27
EP2944306B1 (en) 2021-01-27
US20120087929A1 (en) 2012-04-12
MX2008016124A (es) 2009-01-20
RU2009101226A (ru) 2010-07-27
US20160244505A1 (en) 2016-08-25
ZA200809827B (en) 2011-10-26
US8481046B2 (en) 2013-07-09
US20210340220A1 (en) 2021-11-04
US20100075903A1 (en) 2010-03-25
SI2364691T1 (sl) 2013-08-30
SI2944306T1 (sl) 2021-04-30
RU2432155C3 (ru) 2017-11-17
JP5597271B2 (ja) 2014-10-01
EP2029103A2 (en) 2009-03-04
KR101406811B1 (ko) 2014-06-12
US20190031735A1 (en) 2019-01-31
US10464992B2 (en) 2019-11-05
PT2364691E (pt) 2013-05-15
HUE053612T2 (hu) 2021-07-28
EP2944306A1 (en) 2015-11-18
BRPI0713749A2 (pt) 2012-11-06
PL2364691T3 (pl) 2013-08-30
US10400025B2 (en) 2019-09-03
IL195788A0 (en) 2009-09-01
CN101478949A (zh) 2009-07-08
US8802107B2 (en) 2014-08-12
AU2007261536C1 (en) 2025-08-14
US7608261B2 (en) 2009-10-27
US20200131246A1 (en) 2020-04-30
US12331099B2 (en) 2025-06-17
US11066458B2 (en) 2021-07-20
US11732024B2 (en) 2023-08-22
US20200017572A1 (en) 2020-01-16
US9580489B2 (en) 2017-02-28
JP2013151514A (ja) 2013-08-08
EP2364691B1 (en) 2013-04-24
CN104434770A (zh) 2015-03-25
US8092803B2 (en) 2012-01-10
ES2861898T3 (es) 2021-10-06
WO2007149334A3 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
IL195788A0 (en) Vegf antagonist formulations suitable for intravitreal administration
IL227215A (en) Vegf antagonists
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
PL2124556T3 (pl) Kompozycje farmaceutyczne
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
IL194366A0 (en) Solid dosage formulations
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
GB0614586D0 (en) Pharmaceutical Formulation
EP2109454A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1
ZA201007197B (en) Raloxifene pharmaceutical formulations
IL198160A0 (en) Pharmaceutical formulations
GB0612556D0 (en) Topical pharmaceutical formulations
GB0615461D0 (en) Pharmaceutical formulations
GB0713093D0 (en) Pharmaceutical formulations
HU0600938D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
GB0611079D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions
GB0622964D0 (en) Pharmaceutical compositions
HU0600939D0 (en) Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions
ZA200904725B (en) GLP-1 Pharmaceutical compositions